Nucleix
Signal active
Organization
Contact Information
Overview
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.
Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
About
Industries
Information Technology, Biotechnology, Health Care, Manufacturing, Medical Device, Personal Health
Founded
2008
Employees
11-50
Headquarters locations
Asia
Social
N/A
Profile Resume
Nucleix headquartered in Asia, operates in the Information Technology, Biotechnology, Health Care, Manufacturing, Medical Device, Personal Health sector. The company focuses on Information Technology and has secured $10.0B in funding across 120 round(s). With a team of 11-50 employees, Nucleix is actively contributing to advancements in Information Technology. Their latest funding round, Seed Round - Nucleix, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
3
Lead Investors
0
Total Funding Amount
$83.0M
Details
1
Nucleix has raised a total of $83.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2016 | Seed | 3.0M |
Investors
Nucleix is funded by 26 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Aurum Ventures MKI | - | FUNDING ROUND - Aurum Ventures MKI | 3.0M |
| OrbiMed | - | FUNDING ROUND - OrbiMed | 3.0M |
| Nucleix | - | FUNDING ROUND - Nucleix | 3.0M |
| Zohar Zisapel | - | FUNDING ROUND - Zohar Zisapel | 3.0M |
Recent Activity
There is no recent news or activity for this profile.